ABVC BioPharma (ABVC)
Botanical drug and vitreous-device developer using a partnership-led licensing model.
Something off on this page? Send us feedback.
Develops botanical-derived drug candidates and the Vitargus vitreous-substitute device, with potential economics from licensing, contingent payments and BioKey contract development/manufacturing services. Pivotal development and commercialization may be assigned to partners and subsidiary platforms.
Develops botanical-derived drug candidates and the Vitargus vitreous-substitute device for central nervous system, oncology/hematology and ophthalmology indications. The pipeline is generally advanced through proof-of-concept clinical work, while in-licensed technology and academic research relationships supply key assets.
Potential economics come from licensing rights, equity consideration, milestones and royalties, alongside contract development and manufacturing services through BioKey. Corporate operations span Fremont, California and Taiwan, with clinical and licensing activity across the United States, Taiwan, Australia and Thailand.
Out-licensees and majority-owned platforms carry much of the pivotal development, registration, manufacturing and commercialization work. Clinical progress, approvals, partner financing and execution govern payment realization, while the group retains licensing rights, equity participation or contingent economics.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $94.4K · Total debt $1.8M · Total assets $19.4M · Shareholders' equity $10.3M
- Revenue
- $0
- Operating income
- −$779.5K
- Net income
- −$736.9K
No dividends on record.
| Insiders1 holder · as of Jul 12, 2022 | 2.97% | 790.9K shares | |
| Otherremainder | 97.03% | 25.86M shares |
26.65M company shares as of Sep 3, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
JiangInsider | 2.97% | 790,881 | 13Dfiled Jul 12, 2022 ↗ |
Lind Global Fund II LPInstitution | —9.90% of class, as filed | — | 13Gfiled Aug 7, 2023 ↗ |
Tsung Shann Jiang1Insiderdirector, officer: CSO and Director | 4.54% | 1.21M | Form 4filed Nov 15, 2021 ↗ |
Shuling Jiang2Insiderdirector, 10 percent owner | 2.97% | 790,881 | Form 4filed Jul 12, 2022 ↗ |
Eugene Jiang1Insiderdirector, officer: Chairman of the Board & CBO | 0.27% | 73,272 | Form 4filed Nov 15, 2021 ↗ |
| See all 13 → | |||
- Last filed Nov 15, 2021; leaving the company requires no filing. Not in the bar.
- Last filed Jul 12, 2022; leaving the company requires no filing. Not in the bar.
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
Nothing filed in the last 12 months.
- Eli Lilly
Established MDD medicines overlap with two depression programs.
- Bristol-Myers Squibb
Established MDS and pancreatic-cancer therapies span two programs.
- Merck
KEYTRUDA directly addresses high-risk and metastatic TNBC.
- Takeda (ADR)
Vyvanse is an incumbent treatment in adult ADHD.
- Alcon
Vitreoretinal systems reach the same Vitargus surgical users.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| ABVC BioPharma | $0.8910 | +1.74% | $22.5M | — | — | — | −40,606.4% |
| Eli Lilly | $1,167.77 | +0.72% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Bristol-Myers Squibb | $67.65 | −0.01% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Merck | $151.72 | +0.05% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| Takeda (ADR) | $18.73 | +1.55% | $58.65B | 51.2 | 56.7 | 2.0 | +5.8% |
| Alcon | $72.68 | +0.62% | $35.23B | 55.6 | 18.8 | 3.3 | +7.5% |
| Median | 51.2 | 18.8 | 3.3 | +5.8% |